Abstract:Multiple sclerosis (MS) is a complex autoimmune disease, and several therapies for MS have been developed and widely used. However, existing medications for MS were far from satisfactory due to their failure to suppress relapses and alleviate disease progression. Novel drug targets for MS prevention are still needed. We performed Mendelian randomization (MR) to explore potential drug targets for MS using summary statistics from the International Multiple Sclerosis Genetics Consortium (NCase = 47,429, NControl = 68,374) and further replicated in UK Biobank (NCase = 1,356, NControl = 395,209) and FinnGen cohorts (NCase = 1,326, NControl = 359,815). Genetic instruments for 734 plasma and 154 cerebrospinal fluid (CSF) proteins were obtained from recently published genome-wide association studies (GWAS). The reverse causality detection using bidirectional MR analysis and Steiger filtering, Bayesian colocalization, and phenotype scanning that searched previously-reported genetic variant-trait associations were implemented to consolidate the MR findings further. In addition, the protein-protein interaction (PPI) network was performed to reveal potential associations among proteins and/ or present MS medications. At Bonferroni significance (P < 5.63×10−5), MR analysis revealed six protein-MS pairs. In plasma, per SD increase in FCRL3, TYMP and AHSG had a protective effect. Odds ratio (OR) for the proteins above were 0.83 (95% confidence interval [CI], 0.79-0.89), 0.59 (95% CI, 0.48-0.71), and 0.88 (95% CI, 0.83-0.94), respectively. In CSF, per 10-fold increase in MMEL1 (OR, 5.03; 95% CI, 3.42-7.41) increased the risk of MS, while SLAMF7 (OR, 0.42; 95% CI, 0.29-0.60) and CD5L (OR, 0.30; 95%CI, 0.18-0.52) decreased the risk. None of the six above proteins had reverse causality. Bayesian colocalization suggested that FCRL3 (coloc.abf-posterior probability of hypothesis 4 [PPH4] = 0.889), TYMP (coloc.susie-PPH4 = 0.896), AHSG (coloc.abf-PPH4 = 0.957, coloc.susie-PPH4 = 0.973), MMEL1 (coloc.abf-PPH4 = 0.930), and SLAMF7 (coloc.abf-PPH4 = 0.947) shared the same variant with MS. FCRL3, TYMP, and SLAMF7 interacted with target proteins of current MS medications. MMEL1 was replicated in both UK Biobank and FinnGen cohorts. Our integrative analysis suggested that genetically-determined levels of circulating FCRL3, TYMP, AHSG, CSF MMEL1, and SLAMF7 had causal effects on MS risk. These findings suggested those five proteins might be promising drug targets for MS and warrant further clinical investigation, especially FCRL3 and SLAMF7.

Meta-analysis of the Selected Genetic Variants in Immune-Related Genes and Multiple Sclerosis Risk

Meta-Analysis Of The Il23r And Il12b Polymorphisms In Multiple Sclerosis

Meta-analysis of FOXP3 Gene Rs3761548 and Rs2232365 Polymorphism and Multiple Sclerosis Susceptibility

Functional relevance for multiple sclerosis-associated genetic variants

Integrative analysis revealed potential causal genetic and epigenetic factors for multiple sclerosis

Association between the CD24 Ala57Val polymorphism and risk for multiple sclerosis and systemic lupus erythematosus: a meta-analysis

Genetic Variants Regulate NR1H3 Expression and Contribute to Multiple Sclerosis Risk.

Association between the IL7R T244I polymorphism and multiple sclerosis: a meta-analysis

Gene-Based Tests of a Genome-Wide Association Study Dataset Highlight Novel Multiple Sclerosis Risk Genes

The Polymorphisms Of The Tnf-Alpha Gene In Multiple Sclerosis?-A Meta-Analysis

The Polymorphisms of the TNF -Α Gene in Multiple Sclerosis?—a Meta-Analysis

Causal association between the peripheral immunity and the risk and disease severity of multiple sclerosis

Meta-Analysis Of Association Of Micrornas Genetic Variants With Susceptibility To Rheumatoid Arthritis And Systemic Lupus Erythematosus

Four FCRL3 Gene Polymorphisms (FCRL3_3, _5, _6, _8) Confer Susceptibility to Multiple Sclerosis: Results from a Case-Control Study

Variant of EOMES Associated with Increasing Risk in Chinese Patients with Relapsing-remitting Multiple Sclerosis

Meta-Analysis on Associations of RGS1 and IL12A Polymorphisms with Celiac Disease Risk

Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis

Combining gene expression microarrays and Mendelian randomization: exploring key immune-related genes in multiple sclerosis

Association Between VDR Polymorphisms and Multiple Sclerosis: Systematic Review and Updated Meta-Analysis of Case-Control Studies

Integrating Genetic and Proteomic Data to Elucidate the Association Between Immune System and Blood-Brain Barrier Dysfunction with Multiple Sclerosis Risk and Severity

Impact of the Multiple Sclerosis-Associated Genetic Variant CD226 Gly307Ser on Human CD8 T-Cell Functions